Hydroxysteroid 17-beta dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice.
In: Gene Therapy Weekly, 2024-03-22, S. 1030-1030
serialPeriodical
Zugriff:
A recent study published in Gene Therapy Weekly suggests that knocking down the gene Hsd17b13 can potentially alleviate metabolic dysfunction-associated steatotic liver disease (MASLD) in obese mice. The study found that Hsd17b13 expression was elevated in models of MASLD and normalized with prevention of obesity and steatotic liver. Knocking down Hsd17b13 in obese mice improved hepatic steatosis without affecting body weight, adiposity, or glycaemia. The study also revealed that knocking down Hsd17b13 regulated fatty acid and phospholipid metabolism, suggesting that Hsd17b13 could be a therapeutic target for MASLD and liver fibrosis. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Hydroxysteroid 17-beta dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice.
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-03-22, S. 1030-1030 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|